Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||ASTX-660 + Paclitaxel||Preclinical - Cell line xenograft||Actionable||In a preclinical study, combination of ASTX-660 and Taxol (paclitaxel) treatment resulted in tumro regression and achieved partial response in cell line xenograft models of triple-receptor negative breast cancer (Cancer Res 2016;76(14 Suppl):Abstract nr 1287).||detail...|
|PubMed Id||Reference Title||Details|
|The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo||Full reference...|